220 related articles for article (PubMed ID: 15820288)
1. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
[TBL] [Abstract][Full Text] [Related]
2. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
5. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
[TBL] [Abstract][Full Text] [Related]
6. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
[TBL] [Abstract][Full Text] [Related]
7. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).
Lim MJ; Eagle KA; Gore JM; Anderson FA; Dabbous OH; Mehta RH; Granger CB; Fox KA; Spencer FA; Goldberg RJ;
Am J Cardiol; 2005 Oct; 96(7):917-21. PubMed ID: 16188516
[TBL] [Abstract][Full Text] [Related]
8. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
Morrow DA; Sabatine MS; Antman EM; Cannon CP; Braunwald E; Theroux P
Am J Cardiol; 2004 Sep; 94(6):774-6. PubMed ID: 15374786
[TBL] [Abstract][Full Text] [Related]
10. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
White HD
J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
13. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
14. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
15. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
[TBL] [Abstract][Full Text] [Related]
20. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]